Inventors with similar research interests:
Location History:
- Harleysville, PA (US) (1997 - 2004)
- Billerica, MA (US) (2002 - 2006)
- Reading, MA (US) (2008 - 2011)
- Waltham, MA (US) (2017)
- Andover, MA (US) (2005 - 2023)
Company Filing History:
26 out of 4,770 
5 out of 20 
5 out of 576 
Years Active: 1997-2023
Areas of Expertise:
Title: Michael A. Patane: Innovating PPAR Agonists to Combat Disease
Introduction:
In the world of pharmaceutical innovation, there are individuals who stand out for their remarkable contributions to the field. One such figure is Michael A. Patane, a resident of Harleysville, PA (US), who has made significant advancements in the development of PPAR agonists for the treatment of various diseases. With an impressive portfolio of 52 patents, Patane's dedication to scientific research has placed him at the forefront of medical breakthroughs.
Latest Patents:
Patane's recent patents have focused on PPAR agonists, compounds, pharmaceutical compositions, and methods of use. These inventions aim to increase the activity of PPARδ, a protein that plays a crucial role in regulating gene expression and metabolism. The compounds and compositions he has developed show promise in treating PPARδ-related diseases, such as muscular diseases, vascular diseases, demyelinating diseases, and metabolic diseases. Patane's innovative approach to pharmacological solutions brings hope to patients suffering from these conditions.
Career Highlights:
Throughout his career, Patane has worked with renowned companies such as Merck & Company, Inc. and Mitobridge, Inc. (now part of Astellas Pharma Inc.). His collaborations with these esteemed organizations have paved the way for the development of groundbreaking therapies. Merck & Company, Inc., a leading global pharmaceutical company, has provided a platform for Patane to contribute to the advancement of medical science. Mitobridge, Inc., known for its focus on mitochondrial therapeutics, allowed Patane to explore innovative approaches to addressing diseases at the molecular level.
Collaborations:
Patane's collaborations with fellow scientists and researchers have been instrumental in his success. Notable colleagues include Mark G. Bock and Mark E. Duggan, who have worked alongside Patane in various endeavors. These collaborative efforts have fostered a rich exchange of ideas and expertise, resulting in the development of novel therapeutic strategies. By pooling their knowledge and resources, Patane and his colleagues have enhanced their ability to tackle complex medical challenges.
Conclusion:
Michael A. Patane's prolific career and numerous patents exemplify his commitment to pushing the boundaries of scientific knowledge in the field of PPAR agonists. Through his innovative work, Patane aims to improve the lives of individuals affected by PPARδ-related diseases. By combining his expertise with collaborations and affiliations with industry giants such as Merck & Company, Inc. and Mitobridge, Inc., Patane has demonstrated his extraordinary dedication to advancing medical science. His contributions serve as inspiration to aspiring inventors and researchers, driving innovation towards better health and well-being for all.